1
|
Malla R, Srilatha M, Muppala V, Farran B, Chauhan VS, Nagaraju GP. Neoantigens and cancer-testis antigens as promising vaccine candidates for triple-negative breast cancer: Delivery strategies and clinical trials. J Control Release 2024; 370:707-720. [PMID: 38744346 DOI: 10.1016/j.jconrel.2024.05.020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2023] [Revised: 03/15/2024] [Accepted: 05/10/2024] [Indexed: 05/16/2024]
Abstract
Immunotherapy is gaining prominence as a promising strategy for treating triple-negative breast cancer (TNBC). Neoantigens (neoAgs) and cancer-testis antigens (CTAs) are tumor-specific targets originating from somatic mutations and epigenetic changes in cancer cells. These antigens hold great promise for personalized cancer vaccines, as supported by preclinical and early clinical evidence in TNBC. This review delves into the potential of neoAgs and CTAs as vaccine candidates, emphasizing diverse strategies and delivery approaches. It also highlights the current status of vaccination modalities undergoing clinical trials in TNBC therapy. A comprehensive understanding of neoAgs, CTAs, vaccination strategies, and innovative delivery methods is crucial for optimizing neoAg-based immunotherapies in clinical practice.
Collapse
Affiliation(s)
- RamaRao Malla
- Cancer Biology Lab, Department of Biochemistry and Bioinformatics, GITAM School of Science, GITAM (Deemed to be University), Visakhapatnam 530045, Andhra Pradesh, India
| | - Mundla Srilatha
- Department of Biotechnology, Sri Venkateswara University, Tirupati 517502, AP, India
| | - Veda Muppala
- Department of Neuroscience, University of North Carolina, Chapel Hill, NC 27599, USA
| | - Batoul Farran
- Division of Hematology and Oncology, Department of Medicine, Henry Ford Health, Detroit, MI 48202, USA
| | - Virander Singh Chauhan
- Molecular Medicine Group, Molecular Medicines International Centre for Genetic Engineering and Biotechnology, New Delhi, India
| | - Ganji Purnachandra Nagaraju
- Department of Hematology and Oncology, School of Medicine, University of Alabama at Birmingham, Birmingham, AL 35233, USA.
| |
Collapse
|
2
|
Freitas R, Peixoto A, Ferreira E, Miranda A, Santos LL, Ferreira JA. Immunomodulatory glycomedicine: Introducing next generation cancer glycovaccines. Biotechnol Adv 2023; 65:108144. [PMID: 37028466 DOI: 10.1016/j.biotechadv.2023.108144] [Citation(s) in RCA: 9] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2022] [Revised: 03/17/2023] [Accepted: 03/30/2023] [Indexed: 04/09/2023]
Abstract
Cancer remains a leading cause of death worldwide due to the lack of safer and more effective therapies. Cancer vaccines developed from neoantigens are an emerging strategy to promote protective and therapeutic anti-cancer immune responses. Advances in glycomics and glycoproteomics have unveiled several cancer-specific glycosignatures, holding tremendous potential to foster effective cancer glycovaccines. However, the immunosuppressive nature of tumours poses a major obstacle to vaccine-based immunotherapy. Chemical modification of tumour associated glycans, conjugation with immunogenic carriers and administration in combination with potent immune adjuvants constitute emerging strategies to address this bottleneck. Moreover, novel vaccine vehicles have been optimized to enhance immune responses against otherwise poorly immunogenic cancer epitopes. Nanovehicles have shown increased affinity for antigen presenting cells (APCs) in lymph nodes and tumours, while reducing treatment toxicity. Designs exploiting glycans recognized by APCs have further enhanced the delivery of antigenic payloads, improving glycovaccine's capacity to elicit innate and acquired immune responses. These solutions show potential to reduce tumour burden, while generating immunological memory. Building on this rationale, we provide a comprehensive overview on emerging cancer glycovaccines, emphasizing the potential of nanotechnology in this context. A roadmap towards clinical implementation is also delivered foreseeing advances in glycan-based immunomodulatory cancer medicine.
Collapse
Affiliation(s)
- Rui Freitas
- Experimental Pathology and Therapeutics Group, IPO Porto Research Center (CI-IPOP), RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute (IPO Porto), 4200-072 Porto, Portugal; Institute for Research and Innovation in Health (i3S), University of Porto, 4200-135 Porto, Portugal; Porto Comprehensive Cancer Center (P.ccc), 4200-072 Porto, Portugal; Abel Salazar Biomedical Sciences Institute - University of Porto (ICBAS), 4050-313 Porto, Portugal
| | - Andreia Peixoto
- Experimental Pathology and Therapeutics Group, IPO Porto Research Center (CI-IPOP), RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute (IPO Porto), 4200-072 Porto, Portugal; Institute for Research and Innovation in Health (i3S), University of Porto, 4200-135 Porto, Portugal; Porto Comprehensive Cancer Center (P.ccc), 4200-072 Porto, Portugal
| | - Eduardo Ferreira
- Experimental Pathology and Therapeutics Group, IPO Porto Research Center (CI-IPOP), RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute (IPO Porto), 4200-072 Porto, Portugal
| | - Andreia Miranda
- Experimental Pathology and Therapeutics Group, IPO Porto Research Center (CI-IPOP), RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute (IPO Porto), 4200-072 Porto, Portugal; Abel Salazar Biomedical Sciences Institute - University of Porto (ICBAS), 4050-313 Porto, Portugal
| | - Lúcio Lara Santos
- Experimental Pathology and Therapeutics Group, IPO Porto Research Center (CI-IPOP), RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute (IPO Porto), 4200-072 Porto, Portugal; Porto Comprehensive Cancer Center (P.ccc), 4200-072 Porto, Portugal; Abel Salazar Biomedical Sciences Institute - University of Porto (ICBAS), 4050-313 Porto, Portugal; Health School of University Fernando Pessoa, 4249-004 Porto, Portugal; GlycoMatters Biotech, 4500-162 Espinho, Portugal; Department of Surgical Oncology, Portuguese Oncology Institute (IPO Porto), 4200-072 Porto, Portugal
| | - José Alexandre Ferreira
- Experimental Pathology and Therapeutics Group, IPO Porto Research Center (CI-IPOP), RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute (IPO Porto), 4200-072 Porto, Portugal; Porto Comprehensive Cancer Center (P.ccc), 4200-072 Porto, Portugal; GlycoMatters Biotech, 4500-162 Espinho, Portugal.
| |
Collapse
|
3
|
Sorieul C, Papi F, Carboni F, Pecetta S, Phogat S, Adamo R. Recent advances and future perspectives on carbohydrate-based cancer vaccines and therapeutics. Pharmacol Ther 2022; 235:108158. [PMID: 35183590 DOI: 10.1016/j.pharmthera.2022.108158] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2021] [Revised: 01/30/2022] [Accepted: 02/14/2022] [Indexed: 12/13/2022]
Abstract
Carbohydrates are abundantly expressed on the surface of both eukaryotic and prokaryotic cells, often as post translational modifications of proteins. Glycoproteins are recognized by the immune system and can trigger both innate and humoral responses. This feature has been harnessed to generate vaccines against polysaccharide-encapsulated bacteria such as Streptococcus pneumoniae, Hemophilus influenzae type b and Neisseria meningitidis. In cancer, glycosylation plays a pivotal role in malignancy development and progression. Since glycans are specifically expressed on the surface of tumor cells, they have been targeted for the discovery of anticancer preventive and therapeutic treatments, such as vaccines and monoclonal antibodies. Despite the various efforts made over the last years, resulting in a series of clinical studies, attempts of vaccination with carbohydrate-based candidates have proven unsuccessful, primarily due to the immune tolerance often associated with these glycans. New strategies are thus deployed to enhance carbohydrate-based cancer vaccines. Moreover, lessons learned from glycan immunobiology paved the way to the development of new monoclonal antibodies specifically designed to recognize cancer-bound carbohydrates and induce tumor cell killing. Herein we provide an overview of the immunological principles behind the immune response towards glycans and glycoconjugates and the approaches exploited at both preclinical and clinical level to target cancer-associated glycans for the development of vaccines and therapeutic monoclonal antibodies. We also discuss gaps and opportunities to successfully advance glycan-directed cancer therapies, which could provide patients with innovative and effective treatments.
Collapse
|
4
|
Barz M, Nuhn L, Hörpel G, Zentel R. From Self-Organization to Tumor-Immune Therapy: How Things Started and How They Evolved. Macromol Rapid Commun 2022; 43:e2100829. [PMID: 35729069 DOI: 10.1002/marc.202100829] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2021] [Indexed: 11/08/2022]
Affiliation(s)
- Matthias Barz
- Leiden Academic Center for Drug Research (LACDR), Einsteinweg 55, 2333 CC Leiden, The Netherlands.,Department of Dermatology, University Medical Center of the Johannes Gutenberg University Mainz, Langenbeckstraße 1, 55131, Mainz, Germany
| | - Lutz Nuhn
- Max Planck Institute for Polymer Research, Ackermannweg 10, 55128, Mainz, Germany
| | - Gerhard Hörpel
- GBH Gesellschaft für Batterie Know-how mbH, Lerchenhain 84, 48301, Nottuln, Germany
| | - Rudolf Zentel
- Department of Chemistry, Johannes Gutenberg University Mainz, Duesbergweg 10-14, 55128, Mainz, Germany
| |
Collapse
|
5
|
Gruber A, Navarro L, Klinger D. Dual-reactive nanogels for orthogonal functionalization of hydrophilic shell and amphiphilic network. SOFT MATTER 2022; 18:2858-2871. [PMID: 35348179 DOI: 10.1039/d2sm00116k] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Abstract
Amphiphilic nanogels (NGs) combine a soft, water-swollen hydrogel matrix with internal hydrophobic domains. While these domains can encapsulate hydrophobic cargoes, the amphiphilic particle surface can reduce colloidal stability and/or limit biological half-life. Therefore, a functional hydrophilic shell is needed to shield the amphiphilic network and tune interactions with biological systems. To adjust core and shell properties independently, we developed a synthetic strategy that uses preformed dual-reactive nanogels. In a first step, emulsion copolymerization of pentafluorophenyl methacrylate (PFPMA) and a reduction-cleavable crosslinker produced precursor particles for subsequent network modification. Orthogonal shell reactivity was installed by using an amphiphilic block copolymer (BCP) surfactant during this particle preparation step. Here, the hydrophilic block poly(polyethylene glycol methyl ether methacrylate) (PPEGMA) contains a reactive alkyne end group for successive functionalization. The hydrophobic block (P(PFPMA-co-MAPMA) contains random methacryl-amido propyl methacrylamide (MAPMA) units to covalently attach the surfactant to the growing PPFPMA network. In the second step, orthogonal modification of the core and shell was demonstrated. Network functionalization with combinations of hydrophilic (acidic, neutral, or basic) and hydrophobic (cholesterol) groups gave a library of pH- and redox-sensitive amphiphilic NGs. Stimuli-responsive properties were demonstrated by pH-dependent swelling and reduction-induced degradation via dynamic light scattering. Subsequently, copper-catalyzed azide-alkyne cycloaddition was used to attach azide-modified rhodamine as model compound to the shell (followed by UV-Vis). Overall, this strategy provides a versatile platform to develop multi-functional amphiphilic nanogels as carriers for hydrophobic cargoes.
Collapse
Affiliation(s)
- Alexandra Gruber
- Institute of Pharmacy (Pharmaceutical Chemistry), Freie Universität Berlin, Königin-Luise-Straße 2-4, 14195 Berlin, Germany.
| | - Lucila Navarro
- Institute of Pharmacy (Pharmaceutical Chemistry), Freie Universität Berlin, Königin-Luise-Straße 2-4, 14195 Berlin, Germany.
| | - Daniel Klinger
- Institute of Pharmacy (Pharmaceutical Chemistry), Freie Universität Berlin, Königin-Luise-Straße 2-4, 14195 Berlin, Germany.
| |
Collapse
|
6
|
Stergiou N, Urschbach M, Gabba A, Schmitt E, Kunz H, Besenius P. The Development of Vaccines from Synthetic Tumor-Associated Mucin Glycopeptides and their Glycosylation-Dependent Immune Response. CHEM REC 2021; 21:3313-3331. [PMID: 34812564 DOI: 10.1002/tcr.202100182] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2021] [Revised: 10/31/2021] [Accepted: 11/02/2021] [Indexed: 12/15/2022]
Abstract
Tumor-associated carbohydrate antigens are overexpressed as altered-self in most common epithelial cancers. Their glycosylation patterns differ from those of healthy cells, functioning as an ID for cancer cells. Scientists have been developing anti-cancer vaccines based on mucin glycopeptides, yet the interplay of delivery system, adjuvant and tumor associated MUC epitopes in the induced immune response is not well understood. The current state of the art suggests that the identity, abundancy and location of the glycans on the MUC backbone are all key parameters in the cellular and humoral response. This review shares lessons learned by us in over two decades of research in glycopeptide vaccines. By bridging synthetic chemistry and immunology, we discuss efforts in designing synthetic MUC1/4/16 vaccines and focus on the role of glycosylation patterns. We provide a brief introduction into the mechanisms of the immune system and aim to promote the development of cancer subunit vaccines.
Collapse
Affiliation(s)
- Natascha Stergiou
- Radionuclide Center, Radiology and Nuclear medicine Amsterdam UMC, VU University, De Boelelaan 1085c, 1081 HV, Amsterdam, the Netherlands
| | - Moritz Urschbach
- Department of Chemistry, Johannes Gutenberg University Mainz, Duesbergweg 10-14, 55128, Mainz, Germany
| | - Adele Gabba
- Department of Chemistry, Johannes Gutenberg University Mainz, Duesbergweg 10-14, 55128, Mainz, Germany
| | - Edgar Schmitt
- Institute of Immunology, University Medical Center Mainz, Langenbeckstr. 1, 55131, Mainz, Germany
| | - Horst Kunz
- Department of Chemistry, Johannes Gutenberg University Mainz, Duesbergweg 10-14, 55128, Mainz, Germany
| | - Pol Besenius
- Department of Chemistry, Johannes Gutenberg University Mainz, Duesbergweg 10-14, 55128, Mainz, Germany
| |
Collapse
|
7
|
Neal T, Parnell AJ, King SM, Beattie DL, Murray MW, Williams NSJ, Emmett SN, Armes SP, Spain SG, Mykhaylyk OO. Control of Particle Size in the Self-Assembly of Amphiphilic Statistical Copolymers. Macromolecules 2021; 54:1425-1440. [PMID: 33583958 PMCID: PMC7879426 DOI: 10.1021/acs.macromol.0c02341] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2020] [Revised: 01/05/2021] [Indexed: 11/29/2022]
Abstract
A range of amphiphilic statistical copolymers is synthesized where the hydrophilic component is either methacrylic acid (MAA) or 2-(dimethylamino)ethyl methacrylate (DMAEMA) and the hydrophobic component comprises methyl, ethyl, butyl, hexyl, or 2-ethylhexyl methacrylate, which provide a broad range of partition coefficients (log P). Small-angle X-ray scattering studies confirm that these amphiphilic copolymers self-assemble to form well-defined spherical nanoparticles in an aqueous solution, with more hydrophobic copolymers forming larger nanoparticles. Varying the nature of the alkyl substituent also influenced self-assembly with more hydrophobic comonomers producing larger nanoparticles at a given copolymer composition. A model based on particle surface charge density (PSC model) is used to describe the relationship between copolymer composition and nanoparticle size. This model assumes that the hydrophilic monomer is preferentially located at the particle surface and provides a good fit to all of the experimental data. More specifically, a linear relationship is observed between the surface area fraction covered by the hydrophilic comonomer required to achieve stabilization and the log P value for the hydrophobic comonomer. Contrast variation small-angle neutron scattering is used to study the internal structure of these nanoparticles. This technique indicates partial phase separation within the nanoparticles, with about half of the available hydrophilic comonomer repeat units being located at the surface and hydrophobic comonomer-rich cores. This information enables a refined PSC model to be developed, which indicates the same relationship between the surface area fraction of the hydrophilic comonomer and the log P of the hydrophobic comonomer repeat units for the anionic (MAA) and cationic (DMAEMA) comonomer systems. This study demonstrates how nanoparticle size can be readily controlled and predicted using relatively ill-defined statistical copolymers, making such systems a viable attractive alternative to diblock copolymer nanoparticles for a range of industrial applications.
Collapse
Affiliation(s)
- Thomas
J. Neal
- Department
of Chemistry, The University of Sheffield, Dainton Building, Sheffield S3 7HF, U.K.
| | - Andrew J. Parnell
- Department
of Physics and Astronomy, The University
of Sheffield, Hicks Building, Sheffield S3 7RH, U.K.
| | - Stephen M. King
- ISIS
Pulsed Neutron and Muon Source, STFC Rutherford Appleton Laboratory, Harwell Campus, Didcot, Oxon OX11 0QX, U.K.
| | - Deborah L. Beattie
- Department
of Chemistry, The University of Sheffield, Dainton Building, Sheffield S3 7HF, U.K.
| | - Martin W. Murray
- AkzoNobel
Decorative Paints, Wexham
Road, Slough, Berkshire SL2 5DS, U.K.
| | | | - Simon N. Emmett
- AkzoNobel
Decorative Paints, Wexham
Road, Slough, Berkshire SL2 5DS, U.K.
| | - Steven P. Armes
- Department
of Chemistry, The University of Sheffield, Dainton Building, Sheffield S3 7HF, U.K.
| | - Sebastian G. Spain
- Department
of Chemistry, The University of Sheffield, Dainton Building, Sheffield S3 7HF, U.K.
| | - Oleksandr O. Mykhaylyk
- Department
of Chemistry, The University of Sheffield, Dainton Building, Sheffield S3 7HF, U.K.
| |
Collapse
|
8
|
Liu Y, Wang Z, Yu F, Li M, Zhu H, Wang K, Meng M, Zhao W. The Adjuvant of α-Galactosylceramide Presented by Gold Nanoparticles Enhances Antitumor Immune Responses of MUC1 Antigen-Based Tumor Vaccines. Int J Nanomedicine 2021; 16:403-420. [PMID: 33469292 PMCID: PMC7813472 DOI: 10.2147/ijn.s273883] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2020] [Accepted: 12/29/2020] [Indexed: 12/11/2022] Open
Abstract
BACKGROUND Therapeutic tumor vaccines are one of the most promising strategies and have attracted great attention in cancer treatment. However, most of them have shown unsatisfactory immunogenicity, there are still few available vaccines for clinical use. Therefore, there is an urgent demand to develop novel strategies to improve the immune efficacy of antitumor vaccines. PURPOSE This study aimed to develop novel adjuvants and carriers to enhance the immune effect of MUC1 glycopeptide antigen-based antitumor vaccines. METHODS An antitumor vaccine was developed, in which MUC1 glycopeptide was used as tumor-associated antigen, α-GalCer served as an immune adjuvant and AuNPs was a multivalent carrier. RESULTS Immunological evaluation results indicated that the constructed vaccines enabled a significant antibody response. FACS analysis and immunofluorescence assay showed that the induced antisera exhibited a specific binding with MUC1 positive MCF-7 cells. Moreover, the induced antibody can mediate CDC to kill MCF-7 cells. Besides stimulating B cells to produce MUC1-specific antibodies, the prepared vaccines also induced MUC1-specific CTLs in vitro. Furthermore, the vaccines significantly delayed tumor development in tumor-bearing mice model. CONCLUSION These results showed that the construction of vaccines by presenting α-GalCer adjuvant and an antigen on gold nanoparticles offers a potential strategy to improve the antitumor response in cancer immunotherapy.
Collapse
MESH Headings
- Adjuvants, Immunologic/administration & dosage
- Adjuvants, Immunologic/pharmacology
- Animals
- Antibodies, Neoplasm/immunology
- Antigens, Neoplasm/immunology
- Bone Marrow Cells/drug effects
- Bone Marrow Cells/metabolism
- Cancer Vaccines/immunology
- Cell Line, Tumor
- Cytokines/metabolism
- Cytotoxicity, Immunologic/drug effects
- Dendritic Cells/drug effects
- Dendritic Cells/metabolism
- Female
- Galactosylceramides/chemical synthesis
- Galactosylceramides/chemistry
- Galactosylceramides/pharmacology
- Gold/pharmacology
- Humans
- Immune Sera/metabolism
- Melanoma/immunology
- Melanoma/pathology
- Metal Nanoparticles/chemistry
- Metal Nanoparticles/ultrastructure
- Mice, Inbred BALB C
- Mice, Inbred C57BL
- Mucin-1/immunology
- Spleen/pathology
- T-Lymphocytes, Cytotoxic/drug effects
- T-Lymphocytes, Cytotoxic/immunology
- Mice
Collapse
Affiliation(s)
- Yonghui Liu
- State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and KLMDASR of Tianjin, Nankai University, Tianjin300353, People’s Republic of China
| | - Zhaoyu Wang
- State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and KLMDASR of Tianjin, Nankai University, Tianjin300353, People’s Republic of China
| | - Fan Yu
- College of Life Sciences, Nankai University, Tianjin300071, People’s Republic of China
| | - Mingjing Li
- State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and KLMDASR of Tianjin, Nankai University, Tianjin300353, People’s Republic of China
| | - Haomiao Zhu
- State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and KLMDASR of Tianjin, Nankai University, Tianjin300353, People’s Republic of China
| | - Kun Wang
- State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and KLMDASR of Tianjin, Nankai University, Tianjin300353, People’s Republic of China
| | - Meng Meng
- State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and KLMDASR of Tianjin, Nankai University, Tianjin300353, People’s Republic of China
| | - Wei Zhao
- State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and KLMDASR of Tianjin, Nankai University, Tianjin300353, People’s Republic of China
| |
Collapse
|
9
|
Transient Multivalent Nanobody Targeting to CD206-Expressing Cells via PH-Degradable Nanogels. Cells 2020; 9:cells9102222. [PMID: 33019594 PMCID: PMC7600184 DOI: 10.3390/cells9102222] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2020] [Revised: 09/23/2020] [Accepted: 09/27/2020] [Indexed: 02/07/2023] Open
Abstract
To target nanomedicines to specific cells, especially of the immune system, nanobodies can be considered as an attractive tool, as they lack the Fc part as compared to traditional antibodies and, thus, prevent unfavorable Fc-receptor mediated mistargeting. For that purpose, we have site-specifically conjugated CD206/MMR-targeting nanobodies to three types of dye-labeled nanogel derivatives: non-degradable nanogels, acid-degradable nanogels (with ketal crosslinks), and single polymer chains (also obtained after nanogel degradation). All of them can be obtained from the same reactive ester precursor block copolymer. After incubation with naïve or MMR-expressing Chinese hamster ovary (CHO) cells, a nanobody mediated targeting and uptake could be confirmed for the nanobody-modified nanocarriers. Thereby, the intact nanogels that display nanobodies on their surface in a multivalent way showed a much stronger binding and uptake compared to the soluble polymers. Based on their acidic pH-responsive degradation potential, ketal crosslinked nanogels are capable of mediating a transient targeting that gets diminished upon unfolding into single polymer chains after endosomal acidification. Such control over particle integrity and targeting performance can be considered as highly attractive for safe and controllable immunodrug delivery purposes.
Collapse
|
10
|
Van Herck S, De Geest BG. Nanomedicine-mediated alteration of the pharmacokinetic profile of small molecule cancer immunotherapeutics. Acta Pharmacol Sin 2020; 41:881-894. [PMID: 32451411 PMCID: PMC7471422 DOI: 10.1038/s41401-020-0425-3] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2020] [Accepted: 04/20/2020] [Indexed: 12/21/2022] Open
Abstract
The advent of immunotherapy is a game changer in cancer therapy with monoclonal antibody- and T cell-based therapeutics being the current flagships. Small molecule immunotherapeutics might offer advantages over the biological drugs in terms of complexity, tissue penetration, manufacturing cost, stability, and shelf life. However, small molecule drugs are prone to rapid systemic distribution, which might induce severe off-target side effects. Nanotechnology could aid in the formulation of the drug molecules to improve their delivery to specific immune cell subsets. In this review we summarize the current efforts in changing the pharmacokinetic profile of small molecule immunotherapeutics with a strong focus on Toll-like receptor agonists. In addition, we give our vision on limitations and future pathways in the route of nanomedicine to the clinical practice.
Collapse
Affiliation(s)
- Simon Van Herck
- Department of Pharmaceutics, Ghent University, Ottergemsesteenweg 460, 9000, Ghent, Belgium
| | - Bruno G De Geest
- Department of Pharmaceutics, Ghent University, Ottergemsesteenweg 460, 9000, Ghent, Belgium.
| |
Collapse
|
11
|
|
12
|
Beckwith DM, Cudic M. Tumor-associated O-glycans of MUC1: Carriers of the glyco-code and targets for cancer vaccine design. Semin Immunol 2020; 47:101389. [PMID: 31926647 DOI: 10.1016/j.smim.2020.101389] [Citation(s) in RCA: 53] [Impact Index Per Article: 13.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/29/2019] [Accepted: 01/01/2020] [Indexed: 02/07/2023]
Abstract
The transformation from normal to malignant phenotype in human cancers is associated with aberrant cell-surface glycosylation. It has frequently been reported that MUC1, the heavily glycosylated cell-surface mucin, is altered in both, expression and glycosylation pattern, in human carcinomas of the epithelium. The presence of incomplete or truncated glycan structures, often capped by sialic acid, commonly known as tumor-associated carbohydrate antigens (TACAs), play a key role in tumor initiation, progression, and metastasis. Accumulating evidence suggests that expression of TACAs is associated with tumor escape from immune defenses. In this report, we will give an overview of the oncogenic functions of MUC1 that are exerted through TACA interactions with endogenous carbohydrate-binding proteins (lectins). These interactions often lead to creation of a pro-tumor microenvironment, favoring tumor progression and metastasis, and tumor evasion. In addition, we will describe current efforts in the design of cancer vaccines with special emphasis on synthetic MUC1 glycopeptide vaccines. Analysis of the key factors that govern structure-based design of immunogenic MUC1 glycopeptide epitopes are described. The role of TACA type, position, and density on observed humoral and cellular immune responses is evaluated.
Collapse
Affiliation(s)
- Donella M Beckwith
- Department of Chemistry and Biochemistry, Charles E. Schmidt College of Science, Florida Atlantic University, 777 Glades Road, Boca Raton, Florida 33431, United States
| | - Maré Cudic
- Department of Chemistry and Biochemistry, Charles E. Schmidt College of Science, Florida Atlantic University, 777 Glades Road, Boca Raton, Florida 33431, United States.
| |
Collapse
|
13
|
Shae D, Baljon JJ, Wehbe M, Becker KW, Sheehy TL, Wilson JT. At the bench: Engineering the next generation of cancer vaccines. J Leukoc Biol 2019; 108:1435-1453. [PMID: 31430398 DOI: 10.1002/jlb.5bt0119-016r] [Citation(s) in RCA: 20] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2019] [Revised: 06/29/2019] [Accepted: 07/25/2019] [Indexed: 12/12/2022] Open
Abstract
Cancer vaccines hold promise as an immunotherapeutic modality based on their potential to generate tumor antigen-specific T cell responses and long-lived antitumor responses capable of combating metastatic disease and recurrence. However, cancer vaccines have historically failed to deliver significant therapeutic benefit in the clinic, which we maintain is due in part to drug delivery challenges that have limited vaccine immunogenicity and efficacy. In this review, we examine some of the known and putative failure mechanisms of common first-generation clinical cancer vaccines, and describe how the rational design of materials engineered for vaccine delivery and immunomodulation can address these shortcomings. First, we outline vaccine design principles for augmenting cellular immunity to tumor antigens and describe how well-engineered materials can improve vaccine efficacy, highlighting recent innovations in vaccine delivery technology that are primed for integration into neoantigen vaccine development pipelines. We also discuss the importance of sequencing, timing, and kinetics in mounting effective immune responses to cancer vaccines, and highlight examples of materials that potentiate antitumor immunity through spatiotemporal control of immunomodulation. Furthermore, we describe several engineering strategies for improving outcomes of in situ cancer vaccines, which leverage local, intratumoral delivery to stimulate systemic immunity. Finally, we highlight recent innovations leveraging nanotechnology for increasing the immunogenicity of the tumor microenvironment (TME), which is critical to enhancing tumor infiltration and function of T cells elicited in response to cancer vaccines. These immunoengineering strategies and tools complement ongoing advances in cancer vaccines as they reemerge as an important component of the immunotherapeutic armamentarium.
Collapse
Affiliation(s)
- Daniel Shae
- Department of Chemical and Biomolecular Engineering, Vanderbilt University, Nashville, Tennessee, USA
| | - Jessalyn J Baljon
- Department of Biomedical Engineering, Vanderbilt University, Nashville, Tennessee, USA
| | - Mohamed Wehbe
- Department of Chemical and Biomolecular Engineering, Vanderbilt University, Nashville, Tennessee, USA
| | - Kyle W Becker
- Department of Chemical and Biomolecular Engineering, Vanderbilt University, Nashville, Tennessee, USA
| | - Taylor L Sheehy
- Department of Chemical and Biomolecular Engineering, Vanderbilt University, Nashville, Tennessee, USA
| | - John Tanner Wilson
- Department of Chemical and Biomolecular Engineering, Vanderbilt University, Nashville, Tennessee, USA.,Department of Biomedical Engineering, Vanderbilt University, Nashville, Tennessee, USA.,Vanderbilt Institute for Infection, Immunology, and Inflammation, Vanderbilt University Medical Center, Nashville, Tennessee, USA.,Vanderbilt Center for Immunobiology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.,Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| |
Collapse
|
14
|
Comberlato A, Paloja K, Bastings MMC. Nucleic acids presenting polymer nanomaterials as vaccine adjuvants. J Mater Chem B 2019; 7:6321-6346. [PMID: 31460563 DOI: 10.1039/c9tb01222b] [Citation(s) in RCA: 22] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Most vaccines developed today include only the antigens that best stimulate the immune system rather than the entire virus or microbe, which makes vaccine production and use safer and easier, though they lack potency to induce acceptable immunity and long-term protection. The incorporation of additional immune stimulating components, named adjuvants, is required to generate a strong protective immune response. Nucleic acids (DNA and RNA) and their synthetic analogs are promising candidates as vaccine adjuvants activating Toll-like receptors (TLRs). Additionally, in the last few years several nanocarriers have emerged as platforms for targeted co-delivery of antigens and adjuvants. In this review, we focus on the recent developments in polymer nanomaterials presenting nucleic acids as vaccine adjuvants. We aim to compare the effectiveness of the various classes of polymers in immune modulating materials (nanoparticles, dendrimers, single-chain particles, nanogels, polymersomes and DNA-based architectures). In particular, we address the critical role of parameters such as size, shape, complexation and release of TLR ligands, cellular uptake, stability, toxicity and potential importance of spatial control in ligand presentation.
Collapse
Affiliation(s)
- Alice Comberlato
- IMX/IBI, EPFL, EPFL-STI-IMX-PBL MXC 340 Station 12, Lausanne, 1015, Switzerland.
| | - Kaltrina Paloja
- IMX/IBI, EPFL, EPFL-STI-IMX-PBL MXC 340 Station 12, Lausanne, 1015, Switzerland.
| | - Maartje M C Bastings
- IMX/IBI, EPFL, EPFL-STI-IMX-PBL MXC 340 Station 12, Lausanne, 1015, Switzerland.
| |
Collapse
|
15
|
Xu W, Rudov AA, Schroeder R, Portnov IV, Richtering W, Potemkin II, Pich A. Distribution of Ionizable Groups in Polyampholyte Microgels Controls Interactions with Captured Proteins: From Blockade and "Levitation" to Accelerated Release. Biomacromolecules 2019; 20:1578-1591. [PMID: 30822384 DOI: 10.1021/acs.biomac.8b01775] [Citation(s) in RCA: 31] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
A striking discovery in our work is that the distribution of ionizable groups in polyampholyte microgels (random and core-shell) controls the interactions with the captured proteins. Polyampholyte microgels are capable to switch reversibly their charges from positive to negative depending on pH. In this work, we synthesized differently structured polyampholyte microgels with controlled amounts and different distribution of acidic and basic moieties as colloidal carriers to study the loading and release of the model protein cytochrome c (cyt-c). Polyampholyte microgels were first loaded with cyt-c using the electrostatic attraction under pH 8 when the microgels were oppositely charged with respect to the protein. Then the protein release was investigated under different pH (3, 6, and 8) both with experimental methods and molecular dynamics simulations. For microgels with a random distribution of ionizable groups complete and accelerated (compared to polyelectrolyte counterpart) release of cyt-c was observed due to electrostatic repulsive interactions. For core-shell structured microgels with defined ionizable groups, it was possible to entrap the protein inside the neutral core through the formation of a positively charged shell, which acts as an electrostatic potential barrier. We postulate that this discovery allows the design of functional colloidal carriers with programmed release kinetics for applications in drug delivery, catalysis, and biomaterials.
Collapse
Affiliation(s)
- Wenjing Xu
- DWI-Leibniz Institute for Interactive Materials e.V. , Forckenbeckstraße 50 , 52074 Aachen , Germany.,Functional and Interactive Polymers, Institute of Technical and Macromolecular Chemistry, RWTH Aachen University , Forckenbeckstraße 50 , 52074 Aachen , Germany
| | - Andrey A Rudov
- DWI-Leibniz Institute for Interactive Materials e.V. , Forckenbeckstraße 50 , 52074 Aachen , Germany.,Physics Department , Lomonosov Moscow State University , GSP-1, 1-2 Leninskiye Gory 119991 Moscow , Russian Federation
| | - Ricarda Schroeder
- DWI-Leibniz Institute for Interactive Materials e.V. , Forckenbeckstraße 50 , 52074 Aachen , Germany.,Functional and Interactive Polymers, Institute of Technical and Macromolecular Chemistry, RWTH Aachen University , Forckenbeckstraße 50 , 52074 Aachen , Germany
| | - Ivan V Portnov
- Physics Department , Lomonosov Moscow State University , GSP-1, 1-2 Leninskiye Gory 119991 Moscow , Russian Federation
| | - Walter Richtering
- Institute of Physical Chemistry, RWTH Aachen University , Landoltweg 2 52056 Aachen , Germany
| | - Igor I Potemkin
- DWI-Leibniz Institute for Interactive Materials e.V. , Forckenbeckstraße 50 , 52074 Aachen , Germany.,Physics Department , Lomonosov Moscow State University , GSP-1, 1-2 Leninskiye Gory 119991 Moscow , Russian Federation.,National Research South Ural State University , Chelyabinsk 454080 , Russian Federation
| | - Andrij Pich
- DWI-Leibniz Institute for Interactive Materials e.V. , Forckenbeckstraße 50 , 52074 Aachen , Germany.,Functional and Interactive Polymers, Institute of Technical and Macromolecular Chemistry, RWTH Aachen University , Forckenbeckstraße 50 , 52074 Aachen , Germany.,Aachen Maastricht Institute for Biobased Materials (AMIBM), Maastricht University , Brightlands Chemelot Campus, Urmonderbaan22 , 6167 RD Geleen , The Netherlands
| |
Collapse
|
16
|
Lybaert L, Vermaelen K, De Geest BG, Nuhn L. Immunoengineering through cancer vaccines – A personalized and multi-step vaccine approach towards precise cancer immunity. J Control Release 2018; 289:125-145. [DOI: 10.1016/j.jconrel.2018.09.009] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2018] [Revised: 09/11/2018] [Accepted: 09/12/2018] [Indexed: 02/07/2023]
|
17
|
Allahverdiyev A, Tari G, Bagirova M, Abamor ES. Current Approaches in Development of Immunotherapeutic Vaccines for Breast Cancer. J Breast Cancer 2018; 21:343-353. [PMID: 30607155 PMCID: PMC6310717 DOI: 10.4048/jbc.2018.21.e47] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2018] [Accepted: 08/27/2018] [Indexed: 01/12/2023] Open
Abstract
Cancer is the leading cause of death worldwide. In developed as well as developing countries, breast cancer is the most common cancer found among women. Currently, treatment of breast cancer consists mainly of surgery, chemotherapy, hormone therapy, and radiotherapy. In recent years, because of increased understanding of the therapeutic potential of immunotherapy in cancer prevention, cancer vaccines have gained importance. Here, we review various immunotherapeutic breast cancer vaccines including peptide-based vaccines, whole tumor cell vaccines, gene-based vaccines, and dendritic cell vaccines. We also discuss novel nanotechnology-based approaches to improving breast cancer vaccine efficiency.
Collapse
Affiliation(s)
- Adil Allahverdiyev
- Department of Bioengineering, Faculty of Chemical and Metallurgical Engineering, Yildiz Technical University, Istanbul, Turkey
| | - Gamze Tari
- Department of Bioengineering, Faculty of Chemical and Metallurgical Engineering, Yildiz Technical University, Istanbul, Turkey
| | - Melahat Bagirova
- Department of Bioengineering, Faculty of Chemical and Metallurgical Engineering, Yildiz Technical University, Istanbul, Turkey
| | - Emrah Sefik Abamor
- Department of Bioengineering, Faculty of Chemical and Metallurgical Engineering, Yildiz Technical University, Istanbul, Turkey
| |
Collapse
|
18
|
Li Q, Guo Z. Recent Advances in Toll Like Receptor-Targeting Glycoconjugate Vaccines. Molecules 2018; 23:molecules23071583. [PMID: 29966261 PMCID: PMC6100623 DOI: 10.3390/molecules23071583] [Citation(s) in RCA: 27] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2018] [Revised: 06/25/2018] [Accepted: 06/28/2018] [Indexed: 02/04/2023] Open
Abstract
Many malignant cell surface carbohydrates resulting from abnormal glycosylation patterns of certain diseases can serve as antigens for the development of vaccines against these diseases. However, carbohydrate antigens are usually poorly immunogenic by themselves, thus they need to be covalently coupled with immunologically active carrier molecules to be functional. The most well established and commonly used carriers are proteins. In recent years, the use of toll-like receptor (TLR) ligands to formulate glycoconjugate vaccines has gained significant attention because TLR ligands can serve not only as carrier molecules but also as built-in adjuvants to form fully synthetic and self-adjuvanting conjugate vaccines, which have several advantages over carbohydrate-protein conjugates and formulated mixtures with external adjuvants. This article reviews recent progresses in the development of conjugate vaccines based on TLR ligands. Two major classes of TLR ligands, lipopeptides and lipid A derivatives will be covered with more focus on monophosohoryl lipid A (MPLA) and related analogs, which are TLR4 ligands demonstrated to be able to provoke T cell-dependent, adaptive immune responses. Corresponding conjugate vaccines have shown promising application potentials to multiple diseases including cancer.
Collapse
Affiliation(s)
- Qingjiang Li
- Department of Chemistry, University of Florida, 214 Leigh Hall, Gainesville, FL 32611, USA.
| | - Zhongwu Guo
- Department of Chemistry, University of Florida, 214 Leigh Hall, Gainesville, FL 32611, USA.
| |
Collapse
|
19
|
Nuhn L, Bolli E, Massa S, Vandenberghe I, Movahedi K, Devreese B, Van Ginderachter JA, De Geest BG. Targeting Protumoral Tumor-Associated Macrophages with Nanobody-Functionalized Nanogels through Strain Promoted Azide Alkyne Cycloaddition Ligation. Bioconjug Chem 2018; 29:2394-2405. [PMID: 29889515 DOI: 10.1021/acs.bioconjchem.8b00319] [Citation(s) in RCA: 46] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Tumor-associated macrophages (TAMs) with high expression levels of the Macrophage Mannose Receptor (MMR, CD206) exhibit a strong angiogenic and immune suppressive activity. Thus, they are a highly attractive target in cancer immunotherapy, with the aim to modulate their protumoral behavior. Here, we introduce polymer nanogels as potential drug nanocarriers which were site-specifically decorated with a Nanobody (Nb) specific for the MMR. Using azide-functionalized RAFT chain transfer agents, they provide access to amphiphilic reactive ester block copolymers that self-assemble into micelles and are afterwards core-cross-linked toward fully hydrophilic nanogels with terminal azide groups on their surface. MMR-targeting Nb can site-selectively be functionalized with one single cyclooctyne moiety by maleimide-cysteine chemistry under mildly reducing conditions which enables successful chemoorthogonal conjugation to the nanogels. The resulting Nb-functionalized nanogels were highly efficient in targeting MMR-expressing cells and TAMs both in vitro and in vivo. We believe that these findings pave the road for targeted eradication or modulation of pro-tumoral MMRhigh TAMs.
Collapse
Affiliation(s)
- Lutz Nuhn
- Department of Pharmaceutics , Ghent University , Ottergemsesteenweg 460 , 9000 Ghent , Belgium.,Cancer Research Institute Ghent (CRIG) , Ghent University , Ottergemsesteenweg 460 , 9000 Ghent , Belgium.,Max-Planck-Institute for Polymer Research , Ackermannweg 10 , 55128 Mainz , Germany
| | - Evangelia Bolli
- Myeloid Cell Immunology Lab , VIB Center for Inflammation Research , Pleinlaan 2 , 1050 Brussels , Belgium.,Lab of Cellular and Molecular Immunology , Vrije Universiteit Brussel , Pleinlaan 2 , 1050 Brussels , Belgium
| | - Sam Massa
- Myeloid Cell Immunology Lab , VIB Center for Inflammation Research , Pleinlaan 2 , 1050 Brussels , Belgium.,Lab of Cellular and Molecular Immunology , Vrije Universiteit Brussel , Pleinlaan 2 , 1050 Brussels , Belgium
| | - Isabel Vandenberghe
- Department of Biochemistry and Microbiology , Ghent University , K. L. Ledeganckstraat 35 , 9000 Ghent , Belgium
| | - Kiavash Movahedi
- Myeloid Cell Immunology Lab , VIB Center for Inflammation Research , Pleinlaan 2 , 1050 Brussels , Belgium.,Lab of Cellular and Molecular Immunology , Vrije Universiteit Brussel , Pleinlaan 2 , 1050 Brussels , Belgium
| | - Bart Devreese
- Department of Biochemistry and Microbiology , Ghent University , K. L. Ledeganckstraat 35 , 9000 Ghent , Belgium
| | - Jo A Van Ginderachter
- Myeloid Cell Immunology Lab , VIB Center for Inflammation Research , Pleinlaan 2 , 1050 Brussels , Belgium.,Lab of Cellular and Molecular Immunology , Vrije Universiteit Brussel , Pleinlaan 2 , 1050 Brussels , Belgium
| | - Bruno G De Geest
- Department of Pharmaceutics , Ghent University , Ottergemsesteenweg 460 , 9000 Ghent , Belgium.,Cancer Research Institute Ghent (CRIG) , Ghent University , Ottergemsesteenweg 460 , 9000 Ghent , Belgium
| |
Collapse
|
20
|
Zhou D, Xu L, Huang W, Tonn T. Epitopes of MUC1 Tandem Repeats in Cancer as Revealed by Antibody Crystallography: Toward Glycopeptide Signature-Guided Therapy. Molecules 2018; 23:molecules23061326. [PMID: 29857542 PMCID: PMC6099590 DOI: 10.3390/molecules23061326] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2018] [Revised: 05/20/2018] [Accepted: 05/22/2018] [Indexed: 02/06/2023] Open
Abstract
Abnormally O-glycosylated MUC1 tandem repeat glycopeptide epitopes expressed by multiple types of cancer have long been attractive targets for therapy in the race against genetic mutations of tumor cells. Glycopeptide signature-guided therapy might be a more promising avenue than mutation signature-guided therapy. Three O-glycosylated peptide motifs, PDTR, GSTA, and GVTS, exist in a tandem repeat HGVTSAPDTRPAPGSTAPPA, containing five O-glycosylation sites. The exact peptide and sugar residues involved in antibody binding are poorly defined. Co-crystal structures of glycopeptides and respective monoclonal antibodies are very few. Here we review 3 groups of monoclonal antibodies: antibodies which only bind to peptide portion, antibodies which only bind to sugar portion, and antibodies which bind to both peptide and sugar portions. The antigenicity of peptide and sugar portions of glyco-MUC1 tandem repeat were analyzed according to available biochemical and structural data, especially the GSTA and GVTS motifs independent from the most studied PDTR. Tn is focused as a peptide-modifying residue in vaccine design, to induce glycopeptide-binding antibodies with cross reactivity to Tn-related tumor glycans, but not glycans of healthy cells. The unique requirement for the designs of antibody in antibody-drug conjugate, bi-specific antibodies, and chimeric antigen receptors are also discussed.
Collapse
Affiliation(s)
- Dapeng Zhou
- Shanghai Pulmonary Hospital Affiliated with Tongji University School of Medicine, Shanghai 200092, China.
| | - Lan Xu
- Laboratory of Antibody Structure, Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai 201203, China.
| | - Wei Huang
- CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences and iHuman Institute, ShanghaiTech University, Shanghai 201203, China.
| | - Torsten Tonn
- Institute for Transfusion Medicine Dresden, German Red Cross Blood Donation Service North-East, D-01307 Dresden, Germany.
- Medical Faculty, Carl Gustav Carus Technical University Dresden, D-01307 Dresden, Germany.
| |
Collapse
|
21
|
Keidel R, Ghavami A, Lugo DM, Lotze G, Virtanen O, Beumers P, Pedersen JS, Bardow A, Winkler RG, Richtering W. Time-resolved structural evolution during the collapse of responsive hydrogels: The microgel-to-particle transition. SCIENCE ADVANCES 2018; 4:eaao7086. [PMID: 29740608 PMCID: PMC5938240 DOI: 10.1126/sciadv.aao7086] [Citation(s) in RCA: 76] [Impact Index Per Article: 12.7] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/18/2017] [Accepted: 02/20/2018] [Indexed: 05/19/2023]
Abstract
Adaptive hydrogels, often termed smart materials, are macromolecules whose structure adjusts to external stimuli. Responsive micro- and nanogels are particularly interesting because the small length scale enables very fast response times. Chemical cross-links provide topological constraints and define the three-dimensional structure of the microgels, whereas their porous structure permits fast mass transfer, enabling very rapid structural adaption of the microgel to the environment. The change of microgel structure involves a unique transition from a flexible, swollen finite-size macromolecular network, characterized by a fuzzy surface, to a colloidal particle with homogeneous density and a sharp surface. In this contribution, we determine, for the first time, the structural evolution during the microgel-to-particle transition. Time-resolved small-angle x-ray scattering experiments and computer simulations unambiguously reveal a two-stage process: In a first, very fast process, collapsed clusters form at the periphery, leading to an intermediate, hollowish core-shell structure that slowly transforms to a globule. This structural evolution is independent of the type of stimulus and thus applies to instantaneous transitions as in a temperature jump or to slower stimuli that rely on the uptake of active molecules from and/or exchange with the environment. The fast transitions of size and shape provide unique opportunities for various applications as, for example, in uptake and release, catalysis, or sensing.
Collapse
Affiliation(s)
- Rico Keidel
- Chair of Technical Thermodynamics, Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen University, Schinkelstrasse 8, 52062 Aachen, Germany
| | - Ali Ghavami
- Institute for Advanced Simulation, Forschungszentrum Jülich, 52425 Jülich, Germany
| | - Dersy M. Lugo
- Institute of Physical Chemistry, RWTH Aachen University, Landoltweg 2, 52056 Aachen, Germany
| | - Gudrun Lotze
- European Synchrotron Radiation Facility (ESRF), ID02–Time-Resolved Ultra Small-Angle X-Ray Scattering, 71 Avenue des Martyrs, CS 40220, 38043 Grenoble Cedex 9, France
| | - Otto Virtanen
- Institute of Physical Chemistry, RWTH Aachen University, Landoltweg 2, 52056 Aachen, Germany
| | - Peter Beumers
- Chair of Technical Thermodynamics, Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen University, Schinkelstrasse 8, 52062 Aachen, Germany
| | - Jan Skov Pedersen
- Interdisciplinary Nanoscience Center (iNANO) and Department of Chemistry, Aarhus University, 8000 Aarhus, Denmark
| | - Andre Bardow
- Chair of Technical Thermodynamics, Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen University, Schinkelstrasse 8, 52062 Aachen, Germany
- Institute of Energy and Climate Research: Energy Systems Engineering (IEK-10), Forschungszentrum Jülich, 52425 Jülich, Germany
| | - Roland G. Winkler
- Institute for Advanced Simulation, Forschungszentrum Jülich, 52425 Jülich, Germany
- Corresponding author. (W.R.); (R.G.W.)
| | - Walter Richtering
- Institute of Physical Chemistry, RWTH Aachen University, Landoltweg 2, 52056 Aachen, Germany
- DWI–Leibniz Institute for Interactive Materials, Forckenbeckstrasse 50, D-52056 Aachen, Germany
- Corresponding author. (W.R.); (R.G.W.)
| |
Collapse
|
22
|
Glaffig M, Stergiou N, Hartmann S, Schmitt E, Kunz H. A Synthetic MUC1 Anticancer Vaccine Containing Mannose Ligands for Targeting Macrophages and Dendritic Cells. ChemMedChem 2017; 13:25-29. [PMID: 29193802 DOI: 10.1002/cmdc.201700646] [Citation(s) in RCA: 39] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2017] [Revised: 11/27/2017] [Indexed: 01/28/2023]
Abstract
A MUC1 anticancer vaccine equipped with covalently linked divalent mannose ligands was found to improve the antigen uptake and presentation by targeting mannose-receptor-positive macrophages and dendritic cells. It induced much stronger specific IgG immune responses in mice than the non-mannosylated reference vaccine. Mannose coupling also led to increased numbers of macrophages, dendritic cells, and CD4+ T cells in the local lymph organs. Comparison of di- and tetravalent mannose ligands revealed an increased binding of the tetravalent version, suggesting that higher valency improves binding to the mannose receptor. The mannose-coupled vaccine and the non-mannosylated reference vaccine induced IgG antibodies that exhibited similar binding to human breast tumor cells.
Collapse
Affiliation(s)
- Markus Glaffig
- Johannes Gutenberg University Mainz, Institute of Organic Chemistry, Duesbergweg 10-14, 55128, Mainz, Germany
| | - Natascha Stergiou
- Johannes Gutenberg University Mainz, University Medical Center Institute of Immunology, Langenbeckstraße 1, Building 708, 55131, Mainz, Germany
| | - Sebastian Hartmann
- Johannes Gutenberg University Mainz, Institute of Organic Chemistry, Duesbergweg 10-14, 55128, Mainz, Germany
| | - Edgar Schmitt
- Johannes Gutenberg University Mainz, University Medical Center Institute of Immunology, Langenbeckstraße 1, Building 708, 55131, Mainz, Germany
| | - Horst Kunz
- Johannes Gutenberg University Mainz, Institute of Organic Chemistry, Duesbergweg 10-14, 55128, Mainz, Germany
| |
Collapse
|
23
|
Van Herck S, Van Hoecke L, Louage B, Lybaert L, De Coen R, Kasmi S, Esser-Kahn AP, David SA, Nuhn L, Schepens B, Saelens X, De Geest BG. Transiently Thermoresponsive Acetal Polymers for Safe and Effective Administration of Amphotericin B as a Vaccine Adjuvant. Bioconjug Chem 2017; 29:748-760. [DOI: 10.1021/acs.bioconjchem.7b00641] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
Affiliation(s)
- Simon Van Herck
- Department of Pharmaceutics, Ghent University, Ottergemsesteenweg 460, 9000 Ghent, Belgium
- Cancer Research Institute Ghent (CRIG), Ghent University, Ghent, Belgium
| | - Lien Van Hoecke
- VIB-UGent Center for Medical Biotechnology, Technologiepark 927, 9052 Ghent, Belgium
- Department of Biomedical Molecular Biology, Ghent University, Ghent B-9052, Belgium
| | - Benoit Louage
- Department of Pharmaceutics, Ghent University, Ottergemsesteenweg 460, 9000 Ghent, Belgium
- Cancer Research Institute Ghent (CRIG), Ghent University, Ghent, Belgium
| | - Lien Lybaert
- Department of Pharmaceutics, Ghent University, Ottergemsesteenweg 460, 9000 Ghent, Belgium
- Cancer Research Institute Ghent (CRIG), Ghent University, Ghent, Belgium
| | - Ruben De Coen
- Department of Pharmaceutics, Ghent University, Ottergemsesteenweg 460, 9000 Ghent, Belgium
- Cancer Research Institute Ghent (CRIG), Ghent University, Ghent, Belgium
| | - Sabah Kasmi
- Department of Pharmaceutics, Ghent University, Ottergemsesteenweg 460, 9000 Ghent, Belgium
- Cancer Research Institute Ghent (CRIG), Ghent University, Ghent, Belgium
| | - Aaron P. Esser-Kahn
- Department of Chemistry, University of California, Irvine, California 92697, United States
| | - Sunil A. David
- Department of Medicinal Chemistry, University of Minnesota, Sixth Street SE, Minneapolis, Minnesota 55455, United States
| | - Lutz Nuhn
- Department of Pharmaceutics, Ghent University, Ottergemsesteenweg 460, 9000 Ghent, Belgium
- Cancer Research Institute Ghent (CRIG), Ghent University, Ghent, Belgium
| | - Bert Schepens
- VIB-UGent Center for Medical Biotechnology, Technologiepark 927, 9052 Ghent, Belgium
- Department of Biomedical Molecular Biology, Ghent University, Ghent B-9052, Belgium
| | - Xavier Saelens
- VIB-UGent Center for Medical Biotechnology, Technologiepark 927, 9052 Ghent, Belgium
- Department of Biomedical Molecular Biology, Ghent University, Ghent B-9052, Belgium
| | - Bruno G. De Geest
- Department of Pharmaceutics, Ghent University, Ottergemsesteenweg 460, 9000 Ghent, Belgium
- Cancer Research Institute Ghent (CRIG), Ghent University, Ghent, Belgium
| |
Collapse
|
24
|
Sun ZY, Chen PG, Liu YF, Shi L, Zhang BD, Wu JJ, Zhao YF, Chen YX, Li YM. Self-Assembled Nano-Immunostimulant for Synergistic Immune Activation. Chembiochem 2017; 18:1721-1729. [PMID: 28618135 DOI: 10.1002/cbic.201700246] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2017] [Indexed: 12/11/2022]
Abstract
Immunotherapy has become one of the most promising therapies for the treatment of diseases. Synthetic immunostimulants and nanomaterial immunostimulant systems are indispensable for the activation of the immune system in cancer immunotherapy. Herein, a strategy for preparing self-assembled nano-immunostimulants (SANIs) for synergistic immune activation is reported. Three immunostimulants self-assemble into nanoparticles through electrostatic interactions. SANIs showed strong synergistic immunostimulation in macrophages. SANIs could also induce a strong antitumor immune response to inhibit tumor growth in mice and act as an efficient adjuvant of antitumor vaccines. Therefore, SANIs may be generally applied in cancer immunotherapy. This novel SANI strategy provides a new way for the development of both immunostimulants and -suppressants.
Collapse
Affiliation(s)
- Zhan-Yi Sun
- Key Lab of Bioorganic Phosphorus and Chemical Biology, Department of Chemistry, Tsinghua University, Beijing, 100084, China
| | - Pu-Guang Chen
- Key Lab of Bioorganic Phosphorus and Chemical Biology, Department of Chemistry, Tsinghua University, Beijing, 100084, China
| | - Yan-Fang Liu
- Key Lab of Bioorganic Phosphorus and Chemical Biology, Department of Chemistry, Tsinghua University, Beijing, 100084, China
| | - Lei Shi
- Key Lab of Bioorganic Phosphorus and Chemical Biology, Department of Chemistry, Tsinghua University, Beijing, 100084, China
| | - Bo-Dou Zhang
- Key Lab of Bioorganic Phosphorus and Chemical Biology, Department of Chemistry, Tsinghua University, Beijing, 100084, China
| | - Jun-Jun Wu
- Key Lab of Bioorganic Phosphorus and Chemical Biology, Department of Chemistry, Tsinghua University, Beijing, 100084, China
| | - Yu-Fen Zhao
- Key Lab of Bioorganic Phosphorus and Chemical Biology, Department of Chemistry, Tsinghua University, Beijing, 100084, China
| | - Yong-Xiang Chen
- Key Lab of Bioorganic Phosphorus and Chemical Biology, Department of Chemistry, Tsinghua University, Beijing, 100084, China
| | - Yan-Mei Li
- Key Lab of Bioorganic Phosphorus and Chemical Biology, Department of Chemistry, Tsinghua University, Beijing, 100084, China
| |
Collapse
|
25
|
Leber N, Nuhn L, Zentel R. Cationic Nanohydrogel Particles for Therapeutic Oligonucleotide Delivery. Macromol Biosci 2017; 17. [PMID: 28605133 DOI: 10.1002/mabi.201700092] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2017] [Revised: 05/04/2017] [Indexed: 02/02/2023]
Abstract
Short pharmaceutical active oligonucleotides such as small interfering RNA (siRNA) or cytidine-phosphate-guanosine (CpG) are considered as powerful therapeutic alternatives, especially to medicate hard-to-treat diseases (e.g., liver fibrosis or cancer). Unfortunately, these molecules are equipped with poor pharmacokinetic properties that prevent them from translation. Well-defined nanosized carriers can provide opportunities to optimize their delivery and guide them to their site of action. Among several concepts, this Feature Article focuses on cationic nanohydrogel particles as a universal delivery system for small anionic molecules including siRNA and CpG. Cationic nanohydrogels are derived from preaggregated precursor block copolymers, which are further cross-linked to obtain well-defined nanoparticles of tunable sizes and with (degradable) cationic cores. Novel opportunities for oligonucleotide delivery in vitro and in vivo with respect to liver fibrosis therapies will be highlighted as well as perspectives toward modulating the immune system. In general, the approach of covalently stabilized cationic carrier systems can contribute to find advanced oligonucleotide therapeutics.
Collapse
Affiliation(s)
- Nadine Leber
- Institute of Organic Chemistry, Johannes Gutenberg University of Mainz, Duesbergweg 10-14, 55128, Mainz, Germany
| | - Lutz Nuhn
- Department of Pharmaceutics, Ghent University, Ottergemsesteenweg 460, 9000, Ghent, Belgium
| | - Rudolf Zentel
- Institute of Organic Chemistry, Johannes Gutenberg University of Mainz, Duesbergweg 10-14, 55128, Mainz, Germany
| |
Collapse
|
26
|
Fang RH, Jiang Y, Fang JC, Zhang L. Cell membrane-derived nanomaterials for biomedical applications. Biomaterials 2017; 128:69-83. [PMID: 28292726 PMCID: PMC5417338 DOI: 10.1016/j.biomaterials.2017.02.041] [Citation(s) in RCA: 284] [Impact Index Per Article: 40.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2017] [Revised: 02/28/2017] [Accepted: 02/28/2017] [Indexed: 02/06/2023]
Abstract
The continued evolution of biomedical nanotechnology has enabled clinicians to better detect, prevent, manage, and treat human disease. In order to further push the limits of nanoparticle performance and functionality, there has recently been a paradigm shift towards biomimetic design strategies. By taking inspiration from nature, the goal is to create next-generation nanoparticle platforms that can more effectively navigate and interact with the incredibly complex biological systems that exist within the body. Of great interest are cellular membranes, which play essential roles in biointerfacing, self-identification, signal transduction, and compartmentalization. In this review, we explore the major ways in which researchers have directly leveraged cell membrane-derived biomaterials for the fabrication of novel nanotherapeutics and nanodiagnostics. Such emerging technologies have the potential to significantly advance the field of nanomedicine, helping to improve upon traditional modalities while also enabling novel applications.
Collapse
Affiliation(s)
- Ronnie H Fang
- Department of NanoEngineering and Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA
| | - Yao Jiang
- Department of NanoEngineering and Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA
| | - Jean C Fang
- Department of NanoEngineering and Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA
| | - Liangfang Zhang
- Department of NanoEngineering and Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA.
| |
Collapse
|
27
|
Walta S, Pergushov DV, Oppermann A, Steinschulte AA, Geisel K, Sigolaeva LV, Plamper FA, Wöll D, Richtering W. Microgels enable capacious uptake and controlled release of architecturally complex macromolecular species. POLYMER 2017. [DOI: 10.1016/j.polymer.2017.05.008] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
28
|
Glaffig M, Stergiou N, Schmitt E, Kunz H. Immunogenicity of a Fully Synthetic MUC1 Glycopeptide Antitumor Vaccine Enhanced by Poly(I:C) as a TLR3-Activating Adjuvant. ChemMedChem 2017; 12:722-727. [PMID: 28440596 DOI: 10.1002/cmdc.201700254] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2017] [Indexed: 11/08/2022]
Abstract
Fully synthetic MUC1 glycopeptide antitumor vaccines have a precisely specified structure and induce a targeted immune response without suppression of the immune response when using an immunogenic carrier protein. However, tumor-associated aberrantly glycosylated MUC1 glycopeptides are endogenous structures, "self-antigens", that exhibit only low immunogenicity. To overcome this obstacle, a fully synthetic MUC1 glycopeptide antitumor vaccine was combined with poly(inosinic acid:cytidylic acid), poly(I:C), as a structurally defined Toll-like receptor 3 (TLR3)-activating adjuvant. This vaccine preparation elicited extraordinary titers of IgG antibodies which strongly bound human breast cancer cells expressing tumor-associated MUC1. Beside the humoral response, the poly(I:C) glycopeptide vaccine induced a pro-inflammatory environment, very important to overcome the immune-suppressive mechanisms, and elicited a strong cellular immune response crucial for tumor elimination.
Collapse
Affiliation(s)
- Markus Glaffig
- Johannes Gutenberg University Mainz, Institute of Organic Chemistry, Duesbergweg 10-14, 55128, Mainz, Germany
| | - Natascha Stergiou
- Johannes Gutenberg University Mainz, University Medical Center, Institute of Immunology, Langenbeckstrasse 1, Geb. 708, 55101, Mainz, Germany
| | - Edgar Schmitt
- Johannes Gutenberg University Mainz, University Medical Center, Institute of Immunology, Langenbeckstrasse 1, Geb. 708, 55101, Mainz, Germany
| | - Horst Kunz
- Johannes Gutenberg University Mainz, Institute of Organic Chemistry, Duesbergweg 10-14, 55128, Mainz, Germany
| |
Collapse
|
29
|
Hu X, Wu T, Bao Y, Zhang Z. Nanotechnology based therapeutic modality to boost anti-tumor immunity and collapse tumor defense. J Control Release 2017; 256:26-45. [PMID: 28434891 DOI: 10.1016/j.jconrel.2017.04.026] [Citation(s) in RCA: 37] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2017] [Revised: 04/15/2017] [Accepted: 04/18/2017] [Indexed: 12/19/2022]
Abstract
Cancer is still the leading cause of death. While traditional treatments such as surgery, chemotherapy and radiotherapy play dominating roles, recent breakthroughs in cancer immunotherapy indicate that the influence of immune system on cancer development is virtually beyond our expectation. Manipulating the immune system to fight against cancer has been thriving in recent years. Further understanding of tumor anatomy provides opportunities to put a brake on immunosuppression by overcoming tumor intrinsic resistance or modulating tumor microenvironment. Nanotechnology which provides versatile engineered approaches to enhance therapeutic effects may potentially contribute to the development of future cancer treatment modality. In this review, we will focus on the application of nanotechnology both in boosting anti-tumor immunity and collapsing tumor defense.
Collapse
Affiliation(s)
| | | | - Yuling Bao
- Tongji School of Pharmacy, PR China; Department of Pharmacy, Tongji Hospital, PR China
| | - Zhiping Zhang
- Tongji School of Pharmacy, PR China; National Engineering Research Center for Nanomedicine, PR China; Hubei Engineering Research Center for Novel Drug Delivery System, HuaZhong University of Science and Technology, Wuhan 430030, PR China.
| |
Collapse
|
30
|
SiRNA-mediated in vivo gene knockdown by acid-degradable cationic nanohydrogel particles. J Control Release 2017; 248:10-23. [DOI: 10.1016/j.jconrel.2016.12.006] [Citation(s) in RCA: 44] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2016] [Revised: 11/23/2016] [Accepted: 12/06/2016] [Indexed: 01/22/2023]
|
31
|
Kramer K, Young SL, Walker GF. Comparative Study of 5'- and 3'-Linked CpG-Antigen Conjugates for the Induction of Cellular Immune Responses. ACS OMEGA 2017; 2:227-235. [PMID: 30023513 PMCID: PMC6044624 DOI: 10.1021/acsomega.6b00368] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 11/06/2016] [Accepted: 01/12/2017] [Indexed: 06/08/2023]
Abstract
Conjugation of CpG to an antigen induces a stronger immune response compared to that of the mixture. This study compares the in vitro immunostimulatory activity of CpG conjugated via either its 5' or 3' end to the model antigen ovalbumin (OVA). CpG modified with an amine at either the 5' or 3' end was conjugated to OVA via a stable bis-aryl hydrazone bond. Similar levels of CpG conjugation to OVA were observed for both conjugates on the basis of the absorbance at 360 nm for the formation of the bis-aryl hydrazone bond, which determined 2.8 ± 0.3 CpGs linked per OVA. Both the 5' and 3' CpG-OVA conjugates had similar size-exclusion chromatography elution profiles. The immunostimulatory properties of the conjugates were determined by dendritic cells (DCs) and T-cells isolated from mice. The activation of DCs was determined by the upregulation of activation markers CD86 and CD40. T-cells were co-cultured with stimulated DCs, and the immunogenicity was determined by measuring T-cell proliferation and interferon γ production. Both the CpG 5'- and 3'-linked conjugates induced the same level (p > 0.5) of DC activation markers, which were significantly higher than those of the untreated control. Similarly, T-cell assays showed no significant difference (p > 0.5) between the 5' and 3' conjugates with respect to T-cell proliferation and interferon γ production. The 5' and 3' conjugates induced T-cell activation significantly higher than the mixture of CpG and OVA. This study showed that the end at which CpG is conjugated to an antigen has no influence on the generation of a T-cell-based immune response in vitro.
Collapse
Affiliation(s)
- Katrin Kramer
- School
of Pharmacy and Department of Pathology, Dunedin School of Medicine, University of Otago, P.O. Box 56, Dunedin 9054, New Zealand
| | - Sarah L. Young
- School
of Pharmacy and Department of Pathology, Dunedin School of Medicine, University of Otago, P.O. Box 56, Dunedin 9054, New Zealand
| | - Greg F. Walker
- School
of Pharmacy and Department of Pathology, Dunedin School of Medicine, University of Otago, P.O. Box 56, Dunedin 9054, New Zealand
| |
Collapse
|
32
|
Liu Y, Wang Y, Yu F, Zhang Z, Yang Z, Zhang W, Wang PG, Zhao W. Potentiating the immune response of MUC1-based antitumor vaccines using a peptide-based nanovector as a promising vaccine adjuvant. Chem Commun (Camb) 2017; 53:9486-9489. [DOI: 10.1039/c7cc04386d] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
We utilize the supramolecular self-assembling peptide of Nap-GDFDFDYDK to construct chemically programmed, self-assembling and self-adjuvant MUC1-based antitumor vaccines.
Collapse
Affiliation(s)
- Yonghui Liu
- State Key Laboratory of Medicinal Chemical Biology
- College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research
- Nankai University
- Tianjin 300353
- P. R. China
| | - Youzhi Wang
- College of Life Sciences
- Nankai University
- Tianjin 300071
- P. R. China
| | - Fan Yu
- College of Life Sciences
- Nankai University
- Tianjin 300071
- P. R. China
| | - Zhenqing Zhang
- State Key Laboratory of Toxicology and Medical Countermeasures
- Beijing Institute of Pharmacology and Toxicology
- Beijing 100850
- P. R. China
| | - Zhimou Yang
- College of Life Sciences
- Nankai University
- Tianjin 300071
- P. R. China
| | - Wenpeng Zhang
- State Key Laboratory of Toxicology and Medical Countermeasures
- Beijing Institute of Pharmacology and Toxicology
- Beijing 100850
- P. R. China
| | - Peng George Wang
- State Key Laboratory of Medicinal Chemical Biology
- College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research
- Nankai University
- Tianjin 300353
- P. R. China
| | - Wei Zhao
- State Key Laboratory of Medicinal Chemical Biology
- College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research
- Nankai University
- Tianjin 300353
- P. R. China
| |
Collapse
|
33
|
Mohr N, Kappel C, Kramer S, Bros M, Grabbe S, Zentel R. Targeting cells of the immune system: mannosylated HPMA–LMA block-copolymer micelles for targeting of dendritic cells. Nanomedicine (Lond) 2016; 11:2679-2697. [DOI: 10.2217/nnm-2016-0167] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023] Open
Abstract
Background: Successful tumor immunotherapy depends on the induction of strong and sustained tumor antigen-specific immune responses by activated antigen-presenting cells (APCs) such as dendritic cells (DCs). Since nanoparticles have the potential to codeliver tumor-specific antigen and DC-stimulating adjuvant in a DC-targeting manner, we wanted to assess the suitability of mannosylated HPMA-LMA block polymers for immunotherapy. Materials & methods: Fluorescence-labeled block copolymer micelles derived from P(HPMA)-block-P(LMA) copolymers and according statistical copolymers were synthesized via RAFT polymerization, and loaded with the APC activator L18-MDP. Both types of copolymers were conjugated with D-mannose to target the mannose receptor as expressed by DCs and macrophages. The extent and specificity of micelle binding and activation of APCs was monitored using mouse spleen cells and bone marrow-derived DC (BMDC). Results: Nontargeting HPMA-LMA statistical copolymers showed strong unspecific cell binding. HPMA-LMA block copolymers bound DC only when conjugated with mannose, and in a mannose receptor-specific manner. Mannosylated HPMA-LMA block copolymers were internalized by DC. DC-targeting HPMA-LMA block copolymers mediated DC activation when loaded with L18-MDP. Conclusion: Mannosylated HPMA-LMA block copolymers are a promising candidate for the delvopment of DC-targeting nanovaccines.
Collapse
Affiliation(s)
- Nicole Mohr
- Institute of Organic Chemistry, Johannes Gutenberg-University Mainz, Duesbergweg 10-14, 55099 Mainz, Germany
| | - Cinja Kappel
- Department of Dermatology, University Medical Center, Johannes Gutenberg-University Mainz, Obere Zahlbacher Straße 63, 55131 Mainz, Germany
| | - Stefan Kramer
- Institute of Organic Chemistry, Johannes Gutenberg-University Mainz, Duesbergweg 10-14, 55099 Mainz, Germany
| | - Matthias Bros
- Department of Dermatology, University Medical Center, Johannes Gutenberg-University Mainz, Obere Zahlbacher Straße 63, 55131 Mainz, Germany
| | - Stephan Grabbe
- Department of Dermatology, University Medical Center, Johannes Gutenberg-University Mainz, Obere Zahlbacher Straße 63, 55131 Mainz, Germany
| | - Rudolf Zentel
- Institute of Organic Chemistry, Johannes Gutenberg-University Mainz, Duesbergweg 10-14, 55099 Mainz, Germany
| |
Collapse
|
34
|
Grabbe S, Landfester K, Schuppan D, Barz M, Zentel R. Nanoparticles and the immune system: challenges and opportunities. Nanomedicine (Lond) 2016; 11:2621-2624. [DOI: 10.2217/nnm-2016-0281] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022] Open
Affiliation(s)
- Stephan Grabbe
- Department of Dermatology, University Medical Center, Johannes Gutenberg-University Mainz, Obere Zahlbacher Straße 63, 55131 Mainz, Germany
| | | | - Detlef Schuppan
- Institute for Translational Immunology, University Medical Center, Johannes Gutenberg-University Mainz, Langenbeckstrasse 1, 55101 Mainz, Germany
| | - Matthias Barz
- Institute of Organic Chemistry, Johannes Gutenberg-University Mainz, Duesbergweg 10–14, 55099 Mainz, Germany
| | - Rudolf Zentel
- Institute of Organic Chemistry, Johannes Gutenberg-University Mainz, Duesbergweg 10–14, 55099 Mainz, Germany
| |
Collapse
|
35
|
Jonuleit H, Bopp T, Becker C. Treg cells as potential cellular targets for functionalized nanoparticles in cancer therapy. Nanomedicine (Lond) 2016; 11:2699-2709. [PMID: 27654070 DOI: 10.2217/nnm-2016-0197] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023] Open
Abstract
Treg cell-mediated immune suppression appears to represent a significant barrier to effective anticancer immune responses and their inactivation or removal is viewed as a potential therapeutic approach. Although suitable tools for selective Treg cell manipulation in man are missing, their number and function can be altered by a number of drugs and biologicals and by reprogramming tumor-infiltrating antigen presenting cells. Nanoparticles offer exceptional new options in drug and gene delivery by prolonging the circulation time of their cargo, protecting it from degradation and promoting its local accumulation in cells and tissues. In tumor therapy, the use of nanoparticles is expected to overcome limitations in drug delivery and provide novel means for cell-specific functional alteration. In this perspective, we summarize strategies suitable for interference with Treg-mediated suppression, discuss the potential use of nanoparticles for this purpose and identify additional, unexplored opportunities.
Collapse
Affiliation(s)
- Helmut Jonuleit
- Department of Dermatology, University Medical Center Mainz, Johannes Gutenberg-University, Mainz, Germany
| | - Tobias Bopp
- Institute for Immunology, University Medical Center Mainz, Johannes Gutenberg-University, Mainz, Germany
| | - Christian Becker
- Department of Dermatology, University Medical Center Mainz, Johannes Gutenberg-University, Mainz, Germany
| |
Collapse
|
36
|
Diken M, Pektor S, Miederer M. Harnessing the potential of noninvasive in vivo preclinical imaging of the immune system: challenges and prospects. Nanomedicine (Lond) 2016; 11:2711-2722. [PMID: 27628499 DOI: 10.2217/nnm-2016-0187] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022] Open
Abstract
Preclinical imaging has become a powerful method for investigation of in vivo processes such as pharmacokinetics of therapeutic substances and visualization of physiologic and pathophysiological mechanisms. These are important aspects to understand diseases and develop strategies to modify their progression with pharmacologic interventions. One promising intervention is the application of specifically tailored nanoscale particles that modulate the immune system to generate a tumor targeting immune response. In this complex interaction between immunomodulatory therapies, the immune system and malignant disease, imaging methods are expected to play a key role on the way to generate new therapeutic strategies. Here, we summarize examples which demonstrate the current potential of imaging methods and develop a perspective on the future value of preclinical imaging of the immune system.
Collapse
Affiliation(s)
- Mustafa Diken
- TRON - Translational Oncology at the University Medical Center of Johannes Gutenberg University gGmbH, Mainz, Germany
| | - Stefanie Pektor
- Department of Nuclear Medicine, University Medical Center Mainz, Mainz, Germany
| | - Matthias Miederer
- Department of Nuclear Medicine, University Medical Center Mainz, Mainz, Germany
| |
Collapse
|
37
|
Vanparijs N, Nuhn L, Paluck SJ, Kokkinopoulou M, Lieberwirth I, Maynard HD, De Geest BG. Core/shell protein-reactive nanogels via a combination of RAFT polymerization and vinyl sulfone postmodification. Nanomedicine (Lond) 2016; 11:2631-2645. [PMID: 27628768 DOI: 10.2217/nnm-2016-0214] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023] Open
Abstract
AIM A promising nanogel vaccine platform was expanded toward antigen conjugation. MATERIALS & METHODS Block copolymers containing a reactive ester solvophobic block and a PEG-like solvophilic block were synthesized via reversible addition-fragmentation chain-transfer polymerization. Following self-assembly in DMSO, the esters allow for core-crosslinking and hydrophilization by amide bond formation with primary amines. Free thiols were accessed at the polymer chain ends through aminolysis of the reversible addition-fragmentation chain-transfer groups, and into the nanogel core by reactive ester conversion with cysteamine. Subsequently, free thiols were converted into vinyl sulfone moieties. RESULTS Despite sterical constraints, nanogel-associated vinyl sulfone moieties remained well accessible for cysteins to enforce protein conjugation successfully. CONCLUSION Our present findings provide a next step toward well-defined vaccine nanoparticles that can co-deliver antigen and a molecular adjuvant.
Collapse
Affiliation(s)
- Nane Vanparijs
- Department of Pharmaceutics, Ghent University, Ottergemsesteenweg 460, 9000 Ghent, Belgium.,Department of Chemistry & Biochemistry & California NanoSystems Institute, University of California, Los Angeles, 607 Charles E Young Drive East, Los Angeles, CA 90095, USA
| | - Lutz Nuhn
- Department of Pharmaceutics, Ghent University, Ottergemsesteenweg 460, 9000 Ghent, Belgium
| | - Samantha J Paluck
- Department of Chemistry & Biochemistry & California NanoSystems Institute, University of California, Los Angeles, 607 Charles E Young Drive East, Los Angeles, CA 90095, USA
| | - Maria Kokkinopoulou
- Max Planck Institute for Polymer Research, Ackermannweg 10, 55128 Mainz, Germany
| | - Ingo Lieberwirth
- Max Planck Institute for Polymer Research, Ackermannweg 10, 55128 Mainz, Germany
| | - Heather D Maynard
- Department of Chemistry & Biochemistry & California NanoSystems Institute, University of California, Los Angeles, 607 Charles E Young Drive East, Los Angeles, CA 90095, USA
| | - Bruno G De Geest
- Department of Pharmaceutics, Ghent University, Ottergemsesteenweg 460, 9000 Ghent, Belgium
| |
Collapse
|
38
|
Immunological Evaluation of Recent MUC1 Glycopeptide Cancer Vaccines. Vaccines (Basel) 2016; 4:vaccines4030025. [PMID: 27472370 PMCID: PMC5041019 DOI: 10.3390/vaccines4030025] [Citation(s) in RCA: 47] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2016] [Revised: 07/13/2016] [Accepted: 07/21/2016] [Indexed: 12/13/2022] Open
Abstract
Aberrantly glycosylated mucin 1 (MUC1) is a recognized tumor-specific antigen on epithelial cell tumors. A wide variety of MUC1 glycopeptide anti-cancer vaccines have been formulated by many research groups. Some researchers have used MUC1 alone as an immunogen whereas other groups used different antigenic carrier proteins such as bovine serum albumin or keyhole limpet hemocyanin for conjugation with MUC1 glycopeptide. A variety of adjuvants have been used with MUC1 glycopeptides to improve their immunogenicity. Fully synthetic multicomponent vaccines have been synthesized by incorporating different T helper cell epitopes and Toll-like receptor agonists. Some vaccine formulations utilized liposomes or nanoparticles as vaccine delivery systems. In this review, we discuss the immunological evaluation of different conjugate or synthetic MUC1 glycopeptide vaccines in different tumor or mouse models that have been published since 2012.
Collapse
|
39
|
pH-degradable imidazoquinoline-ligated nanogels for lymph node-focused immune activation. Proc Natl Acad Sci U S A 2016; 113:8098-103. [PMID: 27382168 DOI: 10.1073/pnas.1600816113] [Citation(s) in RCA: 139] [Impact Index Per Article: 17.4] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
Agonists of Toll-like receptors (TLRs) are potent activators of the innate immune system and hold promise as vaccine adjuvant and for anticancer immunotherapy. Unfortunately, in soluble form they readily enter systemic circulation and cause systemic inflammatory toxicity. Here we demonstrate that by covalent ligation of a small-molecule imidazoquinoline-based TLR7/8 agonist to 50-nm-sized degradable polymeric nanogels the potency of the agonist to activate TLR7/8 in in vitro cultured dendritic cells is largely retained. Importantly, imidazoquinoline-ligated nanogels focused the in vivo immune activation on the draining lymph nodes while dramatically reducing systemic inflammation. Mechanistic studies revealed a prevalent passive diffusion of the nanogels to the draining lymph node. Moreover, immunization studies in mice have shown that relative to soluble TLR7/8 agonist, imidazoquinoline-ligated nanogels induce superior antibody and T-cell responses against a tuberculosis antigen. This approach opens possibilities to enhance the therapeutic benefit of small-molecule TLR agonist for a variety of applications.
Collapse
|
40
|
Nuhn L, Kaps L, Diken M, Schuppan D, Zentel R. Reductive Decationizable Block Copolymers for Stimuli-Responsive mRNA Delivery. Macromol Rapid Commun 2016; 37:924-33. [DOI: 10.1002/marc.201600046] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2016] [Revised: 03/09/2016] [Indexed: 12/26/2022]
Affiliation(s)
- Lutz Nuhn
- Institute of Organic Chemistry; Johannes Gutenberg-University Mainz; Duesbergweg 10-14 D-55099 Mainz Germany
- Department of Pharmaceutics; Ghent University; Ottergemsesteenweg 460 B-9000 Ghent Belgium
| | - Leonard Kaps
- Institute of Translational Immunology; University Medical Center of the Johannes Gutenberg-University Mainz; Langenbeckstraße 1 D-55101 Mainz Germany
| | - Mustafa Diken
- TRON - Translational Oncology; University Medical Center of the Johannes Gutenberg-University Mainz; Freiligrathstraße 12 D-55131 Mainz Germany
| | - Detlef Schuppan
- Institute of Translational Immunology; University Medical Center of the Johannes Gutenberg-University Mainz; Langenbeckstraße 1 D-55101 Mainz Germany
- Division of Gastroenterology; Beth Israel Deaconess Medical Center; Harvard Medical School; 330 Brookline Avenue Boston MA 02215 USA
| | - Rudolf Zentel
- Institute of Organic Chemistry; Johannes Gutenberg-University Mainz; Duesbergweg 10-14 D-55099 Mainz Germany
| |
Collapse
|
41
|
Liu Y, Zhang W, He Q, Yu F, Song T, Liu T, Zhang Z, Zhou J, Wang PG, Zhao W. Fully synthetic self-adjuvanting MUC1-fibroblast stimulating lipopeptide 1 conjugates as potential cancer vaccines. Chem Commun (Camb) 2016; 52:10886-9. [DOI: 10.1039/c6cc04623a] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
We have designed and synthesized MUC1-fibroblast stimulating lipopeptide 1 conjugates as potential self-adjuvanting cancer vaccines using a linear solid phase peptide synthesis strategy.
Collapse
Affiliation(s)
- Yonghui Liu
- State Key Laboratory of Medicinal Chemical Biology
- College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research
- Nankai University
- Haihe Education Park
- Tianjin 300353
| | - Wenpeng Zhang
- State Key Laboratory of Toxicology and Medical Countermeasures
- Beijing Institute of Pharmacology and Toxicology
- Beijing 100850
- P. R. China
| | - Qianqian He
- College of Life Sciences
- Nankai University
- Tianjin 300071
- P. R. China
| | - Fan Yu
- College of Life Sciences
- Nankai University
- Tianjin 300071
- P. R. China
| | - Tianbang Song
- State Key Laboratory of Medicinal Chemical Biology
- College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research
- Nankai University
- Haihe Education Park
- Tianjin 300353
| | - Tingting Liu
- State Key Laboratory of Medicinal Chemical Biology
- College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research
- Nankai University
- Haihe Education Park
- Tianjin 300353
| | - Zhenqing Zhang
- State Key Laboratory of Toxicology and Medical Countermeasures
- Beijing Institute of Pharmacology and Toxicology
- Beijing 100850
- P. R. China
| | - Jun Zhou
- College of Life Sciences
- Nankai University
- Tianjin 300071
- P. R. China
| | - Peng George Wang
- State Key Laboratory of Medicinal Chemical Biology
- College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research
- Nankai University
- Haihe Education Park
- Tianjin 300353
| | - Wei Zhao
- State Key Laboratory of Medicinal Chemical Biology
- College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research
- Nankai University
- Haihe Education Park
- Tianjin 300353
| |
Collapse
|
42
|
Sun ZY, Chen PG, Liu YF, Zhang BD, Wu JJ, Chen YX, Zhao YF, Li YM. Multi-component self-assembled anti-tumor nano-vaccines based on MUC1 glycopeptides. Chem Commun (Camb) 2016; 52:7572-5. [DOI: 10.1039/c6cc02000c] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Novel multi-component self-assembled nano-vaccines containing both Pam3CSK4 and CpG were developed based on the strategy of electrostatic interaction.
Collapse
Affiliation(s)
- Z. Y. Sun
- Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology (Ministry of Education)
- Department of Chemistry
- Tsinghua University
- Beijing 100084
- P.R. China
| | - P. G. Chen
- Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology (Ministry of Education)
- Department of Chemistry
- Tsinghua University
- Beijing 100084
- P.R. China
| | - Y. F. Liu
- Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology (Ministry of Education)
- Department of Chemistry
- Tsinghua University
- Beijing 100084
- P.R. China
| | - B. D. Zhang
- Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology (Ministry of Education)
- Department of Chemistry
- Tsinghua University
- Beijing 100084
- P.R. China
| | - J. J. Wu
- Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology (Ministry of Education)
- Department of Chemistry
- Tsinghua University
- Beijing 100084
- P.R. China
| | - Y. X. Chen
- Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology (Ministry of Education)
- Department of Chemistry
- Tsinghua University
- Beijing 100084
- P.R. China
| | - Y. F. Zhao
- Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology (Ministry of Education)
- Department of Chemistry
- Tsinghua University
- Beijing 100084
- P.R. China
| | - Y. M. Li
- Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology (Ministry of Education)
- Department of Chemistry
- Tsinghua University
- Beijing 100084
- P.R. China
| |
Collapse
|
43
|
Kaps L, Nuhn L, Aslam M, Brose A, Foerster F, Rosigkeit S, Renz P, Heck R, Kim YO, Lieberwirth I, Schuppan D, Zentel R. In Vivo Gene-Silencing in Fibrotic Liver by siRNA-Loaded Cationic Nanohydrogel Particles. Adv Healthc Mater 2015; 4:2809-15. [PMID: 26627192 DOI: 10.1002/adhm.201500826] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2015] [Indexed: 12/20/2022]
Abstract
Cationic nanohydrogel particles loaded with anti-Col1α1 siRNA suppress collagen synthesis and deposition in fibrotic mice: Systemically administered 40 nm sized nanogel particles accumulate in collagen-expressing cells in the liver. Their siRNA payload induces a sequence specific in vivo gene knockdown affording an efficient antifibrotic effect in mice with liver fibrosis.
Collapse
Affiliation(s)
- Leonard Kaps
- Institute of Translational Immunology and Research Center for Immune Therapy (FZI); University Medical Center of the Johannes Gutenberg-University Mainz; Langenbeckstraße 1 55101 Mainz Germany
| | - Lutz Nuhn
- Institute of Organic Chemistry; Johannes Gutenberg-University Mainz; Duesbergweg 10-14 55128 Mainz Germany
- Department of Pharmaceutics; Ghent University; Ottergemsesteenweg 460 9000 Ghent Belgium
| | - Misbah Aslam
- Institute of Translational Immunology and Research Center for Immune Therapy (FZI); University Medical Center of the Johannes Gutenberg-University Mainz; Langenbeckstraße 1 55101 Mainz Germany
| | - Alexander Brose
- Institute of Translational Immunology and Research Center for Immune Therapy (FZI); University Medical Center of the Johannes Gutenberg-University Mainz; Langenbeckstraße 1 55101 Mainz Germany
| | - Friedrich Foerster
- Institute of Translational Immunology and Research Center for Immune Therapy (FZI); University Medical Center of the Johannes Gutenberg-University Mainz; Langenbeckstraße 1 55101 Mainz Germany
- Department of Medicine I (Gastroenterology Hepatology, and Nephrology); University Medical Center of Johannes Gutenberg-University Mainz; Langenbeckstraße 1 55101 Mainz Germany
| | - Sebastian Rosigkeit
- Institute of Translational Immunology and Research Center for Immune Therapy (FZI); University Medical Center of the Johannes Gutenberg-University Mainz; Langenbeckstraße 1 55101 Mainz Germany
| | - Patricia Renz
- Max Planck Institute for Polymer Research; Ackermannweg 10 55128 Mainz Germany
| | - Rosario Heck
- Institute of Translational Immunology and Research Center for Immune Therapy (FZI); University Medical Center of the Johannes Gutenberg-University Mainz; Langenbeckstraße 1 55101 Mainz Germany
| | - Yong Ook Kim
- Institute of Translational Immunology and Research Center for Immune Therapy (FZI); University Medical Center of the Johannes Gutenberg-University Mainz; Langenbeckstraße 1 55101 Mainz Germany
| | - Ingo Lieberwirth
- Max Planck Institute for Polymer Research; Ackermannweg 10 55128 Mainz Germany
| | - Detlef Schuppan
- Institute of Translational Immunology and Research Center for Immune Therapy (FZI); University Medical Center of the Johannes Gutenberg-University Mainz; Langenbeckstraße 1 55101 Mainz Germany
- Division of Gastroenterology; Beth Israel Deaconess Medical Center; Harvard Medical School; 330 Brookline Avenue Boston MA 02215 USA
| | - Rudolf Zentel
- Institute of Organic Chemistry; Johannes Gutenberg-University Mainz; Duesbergweg 10-14 55128 Mainz Germany
| |
Collapse
|
44
|
Lepeltier E, Nuhn L, Lehr CM, Zentel R. Not just for tumor targeting: unmet medical needs and opportunities for nanomedicine. Nanomedicine (Lond) 2015; 10:3147-66. [DOI: 10.2217/nnm.15.132] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023] Open
Abstract
During the last 3 decades, nanomedicines have provided novel opportunities to improve the delivery of chemotherapeutics in cancer therapy effectively. However, many principles learnt from there have the potential to be transferred to other diseases. This perspective article, on the one hand, critically reflects the limitations of nanomedicines in tumor therapy and, on the other hand, provides alternative examples of nanomedicinal applications in immunotherapy, noninvasive drug deliveries across epithelial barriers and strategies to combat intra- and extra-cellular bacterial infections. Looking ahead, access to highly complex nanoparticular delivery vehicles given nowadays may allow further improved therapeutic concepts against several diseases in the future too.
Collapse
Affiliation(s)
- Elise Lepeltier
- Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Center for Infection Research (HZI), 66123 Saarbrücken, Germany
| | - Lutz Nuhn
- Department of Pharmaceutics, Ghent University, Ottergemsesteenweg 460, 9000 Ghent, Belgium
| | - Claus-Michael Lehr
- Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Center for Infection Research (HZI), 66123 Saarbrücken, Germany
- Department of Pharmacy, Saarland University, 66123 Saarbrücken, Germany
| | - Rudolf Zentel
- Institute of Organic Chemistry, Johannes Gutenberg-University Mainz, Duesbergweg 10–14, Mainz, Germany
| |
Collapse
|
45
|
Glaffig M, Palitzsch B, Stergiou N, Schüll C, Straßburger D, Schmitt E, Frey H, Kunz H. Enhanced immunogenicity of multivalent MUC1 glycopeptide antitumour vaccines based on hyperbranched polymers. Org Biomol Chem 2015; 13:10150-4. [DOI: 10.1039/c5ob01255d] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
A fully synthetic multivalent MUC1 glycopeptide vaccine based on a hyperbranched polyglycerol core induced IgG antibodies which strongly recognise epithelial tumour cells.
Collapse
Affiliation(s)
- M. Glaffig
- Johannes Gutenberg-University Mainz
- Institute of Organic Chemistry
- 55128 Mainz
- Germany
| | - B. Palitzsch
- Johannes Gutenberg-University Mainz
- Institute of Organic Chemistry
- 55128 Mainz
- Germany
| | - N. Stergiou
- University Medical Center
- Institute of Immunology
- Johannes Gutenberg-University Mainz
- 55101 Mainz
- Germany
| | - C. Schüll
- Johannes Gutenberg-University Mainz
- Institute of Organic Chemistry
- 55128 Mainz
- Germany
| | - D. Straßburger
- Johannes Gutenberg-University Mainz
- Institute of Organic Chemistry
- 55128 Mainz
- Germany
| | - E. Schmitt
- University Medical Center
- Institute of Immunology
- Johannes Gutenberg-University Mainz
- 55101 Mainz
- Germany
| | - H. Frey
- Johannes Gutenberg-University Mainz
- Institute of Organic Chemistry
- 55128 Mainz
- Germany
| | - H. Kunz
- Johannes Gutenberg-University Mainz
- Institute of Organic Chemistry
- 55128 Mainz
- Germany
| |
Collapse
|